Pharmaceutical benefits scheme criteria for the use of tumour necrosis factor-alpha inhibitors in the treatment of ankylosing spondylitis in Australia: are they evidence based?

Malcolm Smith; Michael Ahern

Pharmaceutical benefits scheme criteria for the use of tumour necrosis factor-alpha inhibitors in the treatment of ankylosing spondylitis in Australia: are they evidence based?

Malcolm Smith
, Michael Ahern

Research output: Contribution to journal › Article › peer-review

4 Citations (Scopus)

Original language	English
Pages (from-to)	72-76
Number of pages	5
Journal	Internal Medicine Journal
Volume	36
Issue number	2
Publication status	Published - 2006

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Cite this

@article{9ae0ac6a83564af4affbf722cf1a04da,

title = "Pharmaceutical benefits scheme criteria for the use of tumour necrosis factor-alpha inhibitors in the treatment of ankylosing spondylitis in Australia: are they evidence based?",

author = "Malcolm Smith and Michael Ahern",

year = "2006",

language = "English",

volume = "36",

pages = "72--76",

journal = "Internal Medicine Journal",

issn = "1444-0903",